WAVE Life Sciences Ltd reports results for the quarter ended September 30 - Earnings Summary

• WAVE Life Sciences Ltd WVE.OQ reported a quarterly adjusted loss of 47 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 7 cents. The mean expectation of ten analysts for the quarter was for a loss of 28 cents per share. Wall Street expected results to range from -39 cents to -19 cents per share.

• Revenue rose 115.6% to $-7.68 million from a year ago; analysts expected $16.95 million.

• WAVE Life Sciences Ltd's reported EPS for the quarter was a loss of 47 cents​.

• The company reported a quarterly loss of $61.78 million.

• WAVE Life Sciences Ltd shares had risen by 100.5% this quarter and gained 225.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.3% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for WAVE Life Sciences Ltd is 21.00

This summary was machine generated from LSEG data November 12 at 03:34 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)